Company intelligence / Profile preview

Tallac Therapeutics

Burlingame, California, USAtallactherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company has two programs in clinical trials. They presented first clinical data for TAC-001 at SITC 2023 and new preclinical data on TAC-001 in combination with cancer vaccines at AACR 2024.

Therapeutic areas: Oncology
Modalities: Antibody Drug Conjugates (ADCs)Toll-like Receptor Agonist Antibody Conjugates (TRAAC)oligonucleotide-based ADCs
Industry: Biotech

Drug pipeline

3 assets

TAC-001

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Tallac Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tallac Therapeutics.

Explore the full profile